A multicenter, retrospective study in patients with multiple sclerosis treated with natalizumab in a real-world setting in Japan: The REFIND study.

Nakashima I, Ohashi T, Yokoyama K, Kaida K, Nakahara J, Kondo T, Yoshikura N, Shimizu Y, Nohara C, Sakurai K, Yokote H, Niino M, Yamamura T, Fujihara K, Isobe N, Ochi H, Mori M, Kawachi I, Shimizu F, Kanda M, Tani Y, Fukazawa T

Open source

DOI: 10.1016/j.msard.2026.107007
Published: 2026 Mar
Container: Multiple sclerosis and related disorders
Publisher: Not recorded
Open access: unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/j.msard.2026.107007,
  title = {A multicenter, retrospective study in patients with multiple sclerosis treated with natalizumab in a real-world setting in Japan: The REFIND study.},
  author = {Nakashima I and Ohashi T and Yokoyama K and Kaida K and Nakahara J and Kondo T and Yoshikura N and Shimizu Y and Nohara C and Sakurai K and Yokote H and Niino M and Yamamura T and Fujihara K and Isobe N and Ochi H and Mori M and Kawachi I and Shimizu F and Kanda M and Tani Y and Fukazawa T},
  year = {2026},
  journal = {Multiple sclerosis and related disorders},
  doi = {10.1016/j.msard.2026.107007},
  url = {https://doi.org/10.1016/j.msard.2026.107007}
}

RIS

TY  - JOUR
TI  - A multicenter, retrospective study in patients with multiple sclerosis treated with natalizumab in a real-world setting in Japan: The REFIND study.
AU  - Nakashima I
AU  - Ohashi T
AU  - Yokoyama K
AU  - Kaida K
AU  - Nakahara J
AU  - Kondo T
AU  - Yoshikura N
AU  - Shimizu Y
AU  - Nohara C
AU  - Sakurai K
AU  - Yokote H
AU  - Niino M
AU  - Yamamura T
AU  - Fujihara K
AU  - Isobe N
AU  - Ochi H
AU  - Mori M
AU  - Kawachi I
AU  - Shimizu F
AU  - Kanda M
AU  - Tani Y
AU  - Fukazawa T
PY  - 2026
JO  - Multiple sclerosis and related disorders
DO  - 10.1016/j.msard.2026.107007
UR  - https://doi.org/10.1016/j.msard.2026.107007
ER  -

APA

I, N., T, O., K, Y., K, K., J, N., T, K., N, Y., Y, S., C, N., K, S., H, Y., M, N., T, Y., K, F., N, I., H, O., M, M., I, K., F, S., M, K., Y, T., & T, F. (2026). A multicenter, retrospective study in patients with multiple sclerosis treated with natalizumab in a real-world setting in Japan: The REFIND study.. Multiple sclerosis and related disorders. https://doi.org/10.1016/j.msard.2026.107007

Source records

pubmed · retrieved 2026-09-26T00:34:29.846Z